JPWO2020237173A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020237173A5 JPWO2020237173A5 JP2021569109A JP2021569109A JPWO2020237173A5 JP WO2020237173 A5 JPWO2020237173 A5 JP WO2020237173A5 JP 2021569109 A JP2021569109 A JP 2021569109A JP 2021569109 A JP2021569109 A JP 2021569109A JP WO2020237173 A5 JPWO2020237173 A5 JP WO2020237173A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- nos
- binding domain
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 180
- 239000000427 antigen Substances 0.000 claims 108
- 102000036639 antigens Human genes 0.000 claims 108
- 108091007433 antigens Proteins 0.000 claims 108
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 20
- 210000004027 cell Anatomy 0.000 claims 18
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 201000011510 cancer Diseases 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 102000049583 human ROR1 Human genes 0.000 claims 8
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 6
- 102100039614 Nuclear receptor ROR-alpha Human genes 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims 4
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 238000000684 flow cytometry Methods 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 claims 2
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 241001024304 Mino Species 0.000 claims 2
- 108091007960 PI3Ks Proteins 0.000 claims 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- GYLDXIAOMVERTK-UHFFFAOYSA-N 5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine Chemical compound C12=C(N)N=CN=C2N(C(C)C)N=C1C1=CC=C(OC(N)=N2)C2=C1 GYLDXIAOMVERTK-UHFFFAOYSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 229940045793 B-cell lymphoma-2 inhibitor Drugs 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000003814 Interleukin-10 Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000004388 Interleukin-4 Human genes 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 102000004889 Interleukin-6 Human genes 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000025316 Richter syndrome Diseases 0.000 claims 1
- 208000000389 T-cell leukemia Diseases 0.000 claims 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 229950009821 acalabrutinib Drugs 0.000 claims 1
- WDENQIQQYWYTPO-IBGZPJMESA-N acalabrutinib Chemical compound CC#CC(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C(=O)NC=2N=CC=CC=2)=C2N1C=CN=C2N WDENQIQQYWYTPO-IBGZPJMESA-N 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 201000003444 follicular lymphoma Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 229960001507 ibrutinib Drugs 0.000 claims 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 1
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 claims 1
- 229960003445 idelalisib Drugs 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 1
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229950009216 sapanisertib Drugs 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims 1
- 229960001183 venetoclax Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962852039P | 2019-05-23 | 2019-05-23 | |
| US62/852,039 | 2019-05-23 | ||
| PCT/US2020/034281 WO2020237173A1 (en) | 2019-05-23 | 2020-05-22 | Anti-ror1/anti-cd3 bispecific binding molecules |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022533418A JP2022533418A (ja) | 2022-07-22 |
| JPWO2020237173A5 true JPWO2020237173A5 (https=) | 2023-05-24 |
| JP2022533418A5 JP2022533418A5 (https=) | 2023-05-24 |
| JP7611171B2 JP7611171B2 (ja) | 2025-01-09 |
Family
ID=71078637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021569109A Active JP7611171B2 (ja) | 2019-05-23 | 2020-05-22 | 抗ｒｏｒ１／抗ｃｄ３二重特異性結合分子 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220227866A1 (https=) |
| EP (1) | EP3972999A1 (https=) |
| JP (1) | JP7611171B2 (https=) |
| KR (1) | KR20220012313A (https=) |
| CN (1) | CN113874399B (https=) |
| AU (1) | AU2020277489A1 (https=) |
| BR (1) | BR112021023026A2 (https=) |
| CA (1) | CA3139111A1 (https=) |
| MX (1) | MX2021014193A (https=) |
| TW (1) | TWI899079B (https=) |
| WO (1) | WO2020237173A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023504620A (ja) * | 2019-12-06 | 2023-02-06 | オンコワン・リサーチ・アンド・ディベロップメント・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 抗ｏｘＭＩＦ／抗ＣＤ３二重特異性抗体構築物 |
| CA3166286A1 (en) | 2020-02-07 | 2021-08-12 | Jeffry D. Watkins | Anti-ror1 antibodies and compositions |
| MX2023009022A (es) * | 2021-02-02 | 2023-10-23 | Numab Therapeutics AG | Anticuerpos multiespecificos con especificidad para ror1 y cd3. |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| US12162940B2 (en) | 2021-05-05 | 2024-12-10 | Immatics Biotechnologies Gmbh | BMA031 antigen binding polypeptides |
| TW202320858A (zh) | 2021-07-19 | 2023-06-01 | 美商薩諾管理公司 | 免疫接合物及方法 |
| US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
| WO2023000791A1 (en) * | 2021-07-23 | 2023-01-26 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Antibodies against ror1 and uses thereof |
| WO2023056556A1 (en) * | 2021-10-07 | 2023-04-13 | National Research Council Of Canada | Anti-cd3 monoclonal antibodies and therapeutic constructs |
| JP2024540099A (ja) | 2021-10-28 | 2024-10-31 | ライエル・イミュノファーマ・インコーポレイテッド | Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法 |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3803790B2 (ja) * | 2003-02-17 | 2006-08-02 | 株式会社東北テクノアーチ | 新規なダイアボディ型二重特異性抗体 |
| PL3489261T3 (pl) * | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| EP2981281B1 (en) | 2013-04-03 | 2020-07-15 | IBC Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| CN110627907B (zh) * | 2013-11-04 | 2024-03-29 | 艾科诺斯科技股份有限公司 | 重靶向t细胞的异源二聚免疫球蛋白的产生 |
| US10519248B2 (en) * | 2014-07-25 | 2019-12-31 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
| EP3204415B1 (en) | 2014-10-09 | 2020-06-17 | EngMab Sàrl | Bispecific antibodies against cd3epsilon and ror1 |
| MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| EP3091032A1 (en) | 2015-05-08 | 2016-11-09 | Miltenyi Biotec GmbH | Humanized antibody or fragment thereof specific for cd3 |
| WO2017125897A1 (en) * | 2016-01-21 | 2017-07-27 | Novartis Ag | Multispecific molecules targeting cll-1 |
| KR20180100238A (ko) * | 2016-01-22 | 2018-09-07 | 얀센 바이오테크 인코포레이티드 | 항-ror1 항체, ror1 × cd3 이중특이성 항체, 및 이를 사용하는 방법 |
| TW201730212A (zh) | 2016-02-17 | 2017-09-01 | 宏觀基因股份有限公司 | Ｒｏｒ１－結合分子及其使用方法 |
| WO2018140831A2 (en) * | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| MX2019015057A (es) * | 2017-06-23 | 2020-08-03 | Velosbio Inc | Inmunoconjugados de anticuerpos receptor huérfano similar al receptor tirosina cinasa 1 (ror1). |
| GB201710838D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
| WO2019084060A1 (en) * | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS |
| CA3166286A1 (en) * | 2020-02-07 | 2021-08-12 | Jeffry D. Watkins | Anti-ror1 antibodies and compositions |
-
2020
- 2020-05-22 CN CN202080038180.6A patent/CN113874399B/zh active Active
- 2020-05-22 EP EP20732061.5A patent/EP3972999A1/en active Pending
- 2020-05-22 WO PCT/US2020/034281 patent/WO2020237173A1/en not_active Ceased
- 2020-05-22 US US17/613,251 patent/US20220227866A1/en active Pending
- 2020-05-22 JP JP2021569109A patent/JP7611171B2/ja active Active
- 2020-05-22 MX MX2021014193A patent/MX2021014193A/es unknown
- 2020-05-22 KR KR1020217041982A patent/KR20220012313A/ko not_active Withdrawn
- 2020-05-22 CA CA3139111A patent/CA3139111A1/en active Pending
- 2020-05-22 BR BR112021023026A patent/BR112021023026A2/pt unknown
- 2020-05-22 TW TW109117258A patent/TWI899079B/zh active
- 2020-05-22 AU AU2020277489A patent/AU2020277489A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7464764B2 (ja) | 抗ｒｏｒ１抗体とその作製及び使用方法 | |
| JP7165265B2 (ja) | Ｈｅｒ２／ｐｄ１二重特異性抗体 | |
| JP2020530263A5 (https=) | ||
| CN107660151B (zh) | 抗-cd19抗体和布鲁顿酪氨酸激酶抑制剂的组合及其用途 | |
| JP2020501531A5 (https=) | ||
| TW201920263A (zh) | 檢查點抑制劑雙特異性抗體 | |
| JP2020504723A5 (https=) | ||
| JP2017529838A5 (https=) | ||
| JPWO2020237173A5 (https=) | ||
| CN116948035A (zh) | 多特异性抗体及其制备和使用方法 | |
| JPWO2020198009A5 (https=) | ||
| CN104321343A (zh) | 抗pdgf-c抗体 | |
| CN115210261B (zh) | 抗半乳糖凝集素-9抗体及其用途 | |
| JPWO2020159368A5 (https=) | ||
| JP2022550327A (ja) | 新規の抗ｐｄ－ｌ１抗体 | |
| JP2022550364A (ja) | 新規抗ｐｄ－ｌ１／抗ｌａｇ－３二重特異性抗体およびその使用 | |
| EP4242231A1 (en) | Anti-siglec-15 antibody and application thereof in preparing drug | |
| JP7196311B2 (ja) | 抗ｔｉｍ－３抗体とその利用 | |
| EP4682258A2 (en) | Bispecific antibody and application thereof | |
| RU2021137832A (ru) | Анти-ror1/анти-cd3 биспецифические связывающие молекулы | |
| JPWO2023061505A5 (https=) | ||
| JPWO2020218951A5 (https=) | ||
| CN114616245A (zh) | 一种抗cd38的抗体及其用途 | |
| EP4615874A1 (en) | Cytotoxic bispecific antibodies binding to dr5 and muc16 and uses thereof | |
| JPWO2023178451A5 (https=) |